LGND Ligand Pharmaceuticals Inc
Price (delayed)
$105.22
Market cap
$2.03B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.22
Enterprise value
$1.96B
Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.
Highlights
The gross profit has grown by 29% year-on-year and by 9% since the previous quarter
The revenue has grown by 27% year-on-year and by 10% since the previous quarter
The debt has grown by 15% YoY but it has contracted by 3.4% from the previous quarter
Ligand Pharmaceuticals's net income has plunged by 109% from the previous quarter and by 108% YoY
Ligand Pharmaceuticals's EPS has shrunk by 108% QoQ and by 107% YoY
Key stats
What are the main financial stats of LGND
Market
Valuations
Earnings
Shares outstanding
19.26M
Market cap
$2.03B
Enterprise value
$1.96B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.39
Price to sales (P/S)
11.51
EV/EBIT
352.99
EV/EBITDA
45.69
EV/Sales
11.73
Revenue
$167.13M
Gross profit
$156.06M
Operating income
-$22.61M
Net income
-$4.03M
EBIT
$5.56M
EBITDA
$42.92M
Free cash flow
$95.23M
Per share
Balance sheet
Liquidity
EPS
-$0.22
EPS diluted
-$0.22
Free cash flow per share
$5.21
Book value per share
$43.95
Revenue per share
$9.14
TBVPS
$31.16
Total assets
$941.77M
Total liabilities
$111.34M
Debt
$7.11M
Equity
$830.44M
Working capital
$294.45M
Debt to equity
0.01
Current ratio
8.93
Quick ratio
7.94
Net debt/EBITDA
-1.52
Margins
Efficiency
Dividend
EBITDA margin
25.7%
Gross margin
93.4%
Net margin
-2.4%
Operating margin
-13.5%
Return on assets
-0.4%
Return on equity
-0.5%
Return on invested capital
1.2%
Return on capital employed
0.6%
Return on sales
3.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LGND stock price
How has the Ligand Pharmaceuticals stock price performed over time
Intraday
0.57%
1 week
3.88%
1 month
-4.3%
1 year
33.41%
YTD
-1.8%
QTD
0.08%
Financial performance
How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$167.13M
Gross profit
$156.06M
Operating income
-$22.61M
Net income
-$4.03M
Gross margin
93.4%
Net margin
-2.4%
Ligand Pharmaceuticals's net income has plunged by 109% from the previous quarter and by 108% YoY
The net margin has plunged by 108% from the previous quarter and by 106% YoY
The company's operating income fell by 38% QoQ
The gross profit has grown by 29% year-on-year and by 9% since the previous quarter
Growth
What is Ligand Pharmaceuticals's growth rate over time
Valuation
What is Ligand Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.39
P/S
11.51
EV/EBIT
352.99
EV/EBITDA
45.69
EV/Sales
11.73
Ligand Pharmaceuticals's EPS has shrunk by 108% QoQ and by 107% YoY
LGND's P/B is 19% higher than its last 4 quarters average of 2.0 and 8% higher than its 5-year quarterly average of 2.2
The equity has grown by 18% year-on-year
The revenue has grown by 27% year-on-year and by 10% since the previous quarter
The price to sales (P/S) is 19% higher than the 5-year quarterly average of 9.6
Efficiency
How efficient is Ligand Pharmaceuticals business performance
The company's return on equity has shrunk by 109% QoQ and by 106% YoY
The ROA has shrunk by 108% QoQ and by 106% YoY
Ligand Pharmaceuticals's ROIC has plunged by 94% YoY and by 91% from the previous quarter
Ligand Pharmaceuticals's return on sales has shrunk by 93% YoY and by 92% QoQ
Dividends
What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LGND.
Financial health
How did Ligand Pharmaceuticals financials performed over time
LGND's current ratio is down by 37% year-on-year and by 29% since the previous quarter
Ligand Pharmaceuticals's quick ratio has decreased by 34% YoY and by 26% QoQ
The debt is 99% less than the equity
The equity has grown by 18% year-on-year
The debt has grown by 15% YoY but it has contracted by 3.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.